Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3457263 Alone and in Combination With GLP-1 RA in Patients With Type 2 Diabetes

Next Previous
Search
Trial Profile

Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3457263 Alone and in Combination With GLP-1 RA in Patients With Type 2 Diabetes

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 16 Jan 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dulaglutide (Primary) ; Nisotirostide (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Sponsors Eli Lilly and Company

    • Most Recent Events

    • 10 Jan 2024 Status changed from active, no longer recruiting to completed.
    • 19 Oct 2023 Planned End Date changed from 6 Dec 2023 to 22 Nov 2023.
    • 19 Oct 2023 Planned primary completion date changed from 6 Dec 2023 to 22 Nov 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top